Press release
Globally, More than 12+ Companies are Developing 12+ Therapies in Alpha1-Antitrypsin Deficiency (AATD) Pipeline Landscape | DelveInsight
Alpha1-Antitrypsin Deficiency (AATD) Pipeline
The report provides a detailed description of the drug, including the mechanism of action, type, stage, route of administration, molecule type, clinical studies, inactive pipeline products, and NDA approvals (if any).
The report also covers commercial and clinical activities of the pipeline products from the pre-clinical developmental phase to the marketed stage. Additionally, it presents the ongoing developments in the therapeutics segment, including collaborations, licensing, mergers & acquisitions (M&A), funding, designations, and other product-related details.
Alpha-1 Antitrypsin Deficiency Pipeline Analysis
The report provides insights into:
The report provides detailed insights about companies that are developing therapies in the Alpha-1 Antitrypsin Deficiency Market.
It accesses the different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Alpha-1 Antitrypsin Deficiency treatment.
Alpha-1 Antitrypsin Deficiency key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Alpha-1 Antitrypsin Deficiency Drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Alpha-1 Antitrypsin Deficiency market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Request for Sample PDF:
https://www.delveinsight.com/report-store/alpha-antitrypsin-deficiency-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Alpha-1 Antitrypsin Deficiency Therapeutics Analysis
Globally, there are approx. 12+ key companies are developing therapies for Alpha1-Antitrypsin Deficiency (AATD). Arrowhead Pharmaceuticals has its Alpha1-Antitrypsin Deficiency (AATD) drug candidates in the most advanced stage, i.e., Phase II/III.
Some of the key companies in the Alpha-1 Antitrypsin Deficiency Therapeutics Market include:
• Alnylam Pharmaceuticals
• Arrowhead Pharmaceuticals
• Kamada
• Mereo BioPharma
• Santhera Pharmaceuticals
• Centessa Pharmaceuticals
• Inhibrx
• WaVe Life Sciences
• Promethera Biosciences
• Beam Therapeutics
And many others.
Alpha-1 Antitrypsin Deficiency Therapies covered in the report include:
• ARO AAT (Arrowhead Pharmaceuticals)
• ALN-AAT02 (Alnylam Pharmaceuticals)
And many more
DelveInsight's report covers around 12+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration
Request the Sample PDF to Get a more in-depth Assessment:
https://www.delveinsight.com/sample-request/alpha-antitrypsin-deficiency-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Table of Content
1. Report Introduction
2. Executive Summary
3. Alpha-1 Antitrypsin Deficiency Current Treatment Patterns
4. Alpha-1 Antitrypsin Deficiency - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Alpha-1 Antitrypsin Deficiency Late Stage Products (Phase-III)
7. Alpha-1 Antitrypsin Deficiency Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Alpha-1 Antitrypsin Deficiency Discontinued Products
13. Alpha-1 Antitrypsin Deficiency Product Profiles
14. Alpha-1 Antitrypsin Deficiency Key Companies
15. Alpha-1 Antitrypsin Deficiency Key Products
16. Dormant and Discontinued Products
17. Alpha-1 Antitrypsin Deficiency Unmet Needs
18. Alpha-1 Antitrypsin Deficiency Future Perspectives
19. Alpha-1 Antitrypsin Deficiency Analyst Review
20. Appendix
21. Report Methodology
*The table of contents is not exhaustive; the final content may vary.
Request for the Sample PDF (to get a detailed understanding of the TOC, Tables, and Figures included in the report), at: https://www.delveinsight.com/sample-request/alpha-antitrypsin-deficiency-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Contact Info:
Anuj Rawat
Email: info@delveinsight.com
https://www.delveinsight.com/
Request for Sample Copy of the Report at:
https://www.delveinsight.com/report-store/alpha-antitrypsin-deficiency-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Globally, More than 12+ Companies are Developing 12+ Therapies in Alpha1-Antitrypsin Deficiency (AATD) Pipeline Landscape | DelveInsight here
News-ID: 2688731 • Views: …
More Releases from DelveInsight Business Research
Spinocerebellar Ataxias Pipeline 2025: Comprehensive Clinical Trials and Therapi …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Spinocerebellar Ataxias pipeline constitutes 8+ key companies continuously working towards developing 10+ Spinocerebellar Ataxias treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
"Spinocerebellar Ataxias Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Spinocerebellar Ataxias Market.
The Spinocerebellar…
Presbyopia Market to Evolve Rapidly Over the Next Decade by 2034, DelveInsight O …
The Presbyopia market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Presbyopia pipeline products will significantly revolutionize the Presbyopia market dynamics.
DelveInsight's "Presbyopia Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Presbyopia, historical and forecasted epidemiology as well as the Presbyopia market trends in the United States, EU5 (Germany, Spain, Italy, France,…
Idiopathic Pulmonary Fibrosis Market Insights Highlight Expanding Outlook Till 2 …
DelveInsight's "Idiopathic Pulmonary Fibrosis Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Idiopathic Pulmonary Fibrosis, historical and forecasted epidemiology as well as the Idiopathic Pulmonary Fibrosis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
The latest healthcare forecast report provides an in-depth analysis of Idiopathic Pulmonary Fibrosis, offering comprehensive insights into the Idiopathic Pulmonary Fibrosis revenue trends,…
Myocardial Infarction Market Positioned for Accelerated Development Through 2034 …
DelveInsight's "Myocardial Infarction Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Myocardial Infarction, historical and forecasted epidemiology as well as the Myocardial Infarction market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Myocardial Infarction market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Myocardial Infarction Market Forecast
https://www.delveinsight.com/sample-request/myocardial-infarction-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Some of the…
More Releases for Deficiency
Iron Deficiency And Iron Deficiency Anaemia Treatment Market Size Trends and For …
According to Market Research Intellect, the global Iron Deficiency And Iron Deficiency Anaemia Treatment market under the Internet, Communication and Technology category is expected to register notable growth from 2025 to 2032. Key drivers such as advancing technologies, changing consumer behavior, and evolving market dynamics are poised to shape the trajectory of this market throughout the forecast period.
The market for treating iron deficiency and iron deficiency anaemia is growing steadily…
Iron Deficiency Anemia Market Analysis 2034 | Iron Deficiency Anemia Therapies, …
As per DelveInsight, the Iron Deficiency Anemia Market is anticipated to grow immensely in the coming years owing to the launch of upcoming therapies and the increase in the incident population of Iron Deficiency Anemia in the 7MM.
DelveInsight's "Iron Deficiency Anemia Market Insights, Epidemiology, and Market Forecast 2034 [https://www.delveinsight.com/report-store/iron-deficiency-anemia-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]" report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Iron Deficiency Anemia market size,…
Coagulation Factor Deficiency Market Bridging the Gap: A Growing Coagulation Fac …
Coagulation Factor Deficiency Market worth $9.60 Bn by 2031 - Exclusive Report by InsightAce Analytic Pvt. Ltd.
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Coagulation Factor Deficiency Market- (By Deficiency Type (Hemophilia A, Hemophilia B, Von Willebrand Disease, Factor XI Deficiency, Factor XIII Deficiency, and Others), By Product Type (Plasma-Derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Biologics, Desmopressin, and Others),
By End…
Alpha-1 Antitrypsin Deficiency and Lung Health Beyond Deficiency Breathing New L …
Alpha 1 Lung Disease Market to Record an Exponential CAGR of 19.33% by 2031 - Exclusive Report by InsightAce Analytic Pvt. Ltd.
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Alpha 1 Lung Disease Market - (By Disease Type (Alpha-1 Antitrypsin Deficiency, Chronic Obstructive Pulmonary Disease (COPD), Pulmonary Fibrosis, Bronchiectasis, Others), By Treatment Type (Augmentation Therapy, Bronchodilators, Corticosteroids, Oxygen Therapy, Lung Transplantation, Others),
By…
Global Iron Deficiency Anaemia Treatment Market to be Driven by the Rising Preva …
The 'Global Iron Deficiency Anaemia Treatment Market Size, Report and Forecast 2023-2031' by Expert Market Research gives an extensive outlook of the global iron deficiency anaemia treatment market, assessing the market on the basis of its segments like drug type, route of administration, treatment channel, and major regions.
Iron Deficiency Anaemia Treatment Market Size, Share, Price Trends, Industry Report, Key Players, Major Segments, and Forecast
The key highlights of the report include:
Market…
Growth Hormone Deficiency (GHD) Treatment Market
Growth Hormone Deficiency (GHD) Treatment Market: Overview
The growth hormone deficiency (GHD) treatment market has made some notable strides on the back of the growing role of GH replacement therapy in managing GHD in adults. Advances in understanding clinical syndrome of GHD and understanding of diagnosis are key trends boosting the GHD treatment market. Clinical practices pertaining to pharmacological management of the syndrome in the GHD treatment market have made remarkable…
